Specialty biopharmaceutical company: Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix, Inc. (NASDAQ:OCUL) was founded in 2006 and is headquartered in Bedford, Massachusetts, USA, with 119 full-time employees. It is a biopharmaceutical company that focuses on the development, development and commercialization of its bioabsorbable hydrogel platform technology Used in the treatment of eye diseases.

Ocular Therapeutix

Ocular Therapeutix, Inc. (OCUL):

Ocular Therapeutix’s main product candidates include:

  • DEXTENZA (Dexamethasone insert) for the treatment of postoperative eye pain and inflammation, allergic conjunctivitis and dry eye;
  • OTX-TP (travoprost insert) is used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension;
  • The company is also developing OTX-TIC, which is an anterior chamber injection of Treprostinil implant to reduce intraocular pressure in patients with moderate to severe glaucoma and high intraocular pressure;
  • OTX-TKI, a tyrosine kinase inhibitor for intravitreal injection, can provide hydrogel-based anti-angiogenic preparations for the treatment of wet age-related macular degeneration;
  • In addition, the company also sells ReSure Sealant, a hydrogel-based ophthalmic wound sealant used to seal corneal incisions after cataract surgery;
  • Furthermore, the company is engaged in the pre-clinical development of its hydrogel formulations administered by intravitreal injection to solve diseases and disorders of the back of the eye.

Ocular Therapeutix has signed a cooperation agreement with Regeneron Pharmaceuticals to use its combined platform of hydrogel and macromolecular VEGF targeting compounds for product development and commercialization to treat retinal diseases.

Notify of
Inline Feedbacks
View all Intels

American Film Advertising Company: National CineMedia (NCMI)

Manufacturer of subsea drilling and oil production equipment and offshore ship equipment: Dril-Quip, Inc. (DRQ)